Treatment Patterns and <i>FLT3</i> Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational Study.
Journal Information
Full Title: Ther Clin Risk Manag
Abbreviation: Ther Clin Risk Manag
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Health Care Sciences & Services
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosure Li-Jen Cheng and Prabhuram Krishnan are employees of Astellas Pharma Singapore Pte. Ltd. Christopher H. Young is an employee of Astellas Pharma US Inc. Jia Zhong and Eric Q. Wu are employees of Analysis Group, Inc., an HEOR CRO company contracted by Astellas to undertake analysis. Jianxiang Wang participated in an advisory board for AbbVie. The authors report no other conflicts of interest in this work."
"The study was sponsored by Astellas Pharma Singapore Pte. Ltd. Medical writing support and editorial support were funded by Astellas Pharma, Inc."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025